FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Priority Review for Gamidas Omidubicel

[ Price : $8.95]

FDA accepts for priority review a Gamida Cell BLA for omidubicel for treating patients with blood cancers in need of an allogenic ...

FDA Publishes 48 Product-Specific Guidances

[ Price : $8.95]

FDA publishes 48 new and revised product-specific guidances in its latest batch.

FDA Withdrawing 7 No-Longer-Marketed ANDAs

[ Price : $8.95]

Federal Register notice: FDA withdraws the approval of seven ANDAs from multiple applicants after they notified the agency that th...

North American Diagnostics Recalls Covid Tests

[ Price : $8.95]

North American Diagnostics recalls its Oral Rapid SARS-CoV-2 Rapid Antigen Test Kits because they were distributed without FDA aut...

Beam Hit With Clinical Hold on CAR-T Therapy

[ Price : $8.95]

FDA issues a clinical hold on Beam Therapeutics BEAM-201 and its use in treating relapsed/refractory T-cell acute lymphoblastic le...

Minor Use, Minor Species Reporting Collection

[ Price : $8.95]

Federal Register notice: FDA seeks comments on an information collection entitled Reporting Associated With Designated New Animal ...

ImmunityBio Files BLA for Bladder Cancer Therapy

[ Price : $8.95]

FDA accepts for review an ImmunityBio BLA for its antibody cytokine fusion protein as a treatment for certain patients with Bacill...

Hold Lifted on Celyad Oncology CAR T Therapy

[ Price : $8.95]

FDA removes a clinical hold on Celyad Oncologys CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the company modified the eligibili...

FDA Approves Stelara in Pediatric Psoriatic Arthritis

[ Price : $8.95]

FDA approves Janssens Stelara (ustekinumab) for treating pediatric patients six years of age and older with active psoriatic arthr...

AstraZeneca Scraps Monalizumab Clinical Study

[ Price : $8.95]

AstraZeneca says discontinued a monalizumab study after a planned futility interim analysis of the INTERLINK-1 Phase 3 study did n...